Survodutide
GLP-1/glucagon dual agonist — completed Phase 3 trials in obesity and MASH, not yet FDA-approved.
Last Verified: August 14, 2026
Tier 2 — Investigational / Not Currently Approved Late-Stage Investigational
Survodutide is not FDA-approved for any use, but it has large, completed Phase 3 trials with real published results — a different evidence situation than most Tier 2 compounds. This page describes the mechanism and the actual trial data — not dosing or usage guidance, and not a recommendation to use it. Talk to a doctor before considering it.
What It Is
Survodutide is a peptide developed by Boehringer Ingelheim (in partnership with Zealand Pharma) that acts as a dual agonist at the GLP-1 and glucagon receptors — similar in concept to retatrutide's triple-agonist approach, but targeting two receptors instead of three. The added glucagon-receptor activity is intended to increase energy expenditure alongside the appetite and insulin effects of GLP-1 activity, and is also the basis for its liver-focused research in fatty liver disease.
What the Trials Actually Show
In the Phase 3 SYNCHRONIZE-1 trial, adults with obesity without diabetes lost an average of about 16.6% of body weight on the higher studied dose over 76 weeks, with a substudy showing meaningful reductions in visceral and liver fat. In a separate Phase 3 trial (SYNCHRONIZE-MASLD) in adults with obesity and MASH/MASLD (metabolic dysfunction-associated steatohepatitis), 84.2% of participants achieved at least a 30% reduction in liver fat over 48 weeks, versus 24.3% on placebo, alongside about 12.2% weight loss. The most common side effects reported were mild-to-moderate gastrointestinal symptoms, consistent with the GLP-1 drug class generally.
AJMC — Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss →
Current Regulatory Status — Watch This Space
Survodutide is not FDA-approved and not available by prescription as of this writing, for either obesity or MASH. Boehringer Ingelheim and Zealand Pharma are continuing their Phase 3 programs in both indications. This status could change as trial programs complete and a filing is submitted — check back for updates. Until any approval, it remains available only through unregulated research-chemical channels, with the sourcing and purity risks that implies.